Phlow Corp., a U.S.-based public benefit corporation and contract development and manufacturing organization (CDMO), closed a $36 million Series B capital raise as part of its mission to protect America’s medicine cabinet.

Since its launch in 2020, Phlow has been working to leverage advanced development and manufacturing processes to reimagine the domestic production of key starting materials (KSM), active pharmaceutical ingredients (API), and finished pharmaceutical products that are critical to U.S. healthcare.

The strategic capital raised will be leveraged by Phlow to expand its commercial offerings, including the rapid growth of its CDMO program, cdmoX, that provides a range of customized services to pharmaceutical and biotech companies resulting in reduced production costs, decreased development time, improved quality, and lower negative environmental impact.

Phlow’s U.S.-based R&D laboratory, co-located with the U.S. Pharmacopeia (USP) at the Advanced Pharmaceutical Development Center in Richmond, VA, along with its brand-new manufacturing facilities in Petersburg, VA, will make it possible for Phlow’s customers to bring critical medicine supply chains back to the United States in order to help prevent future disruptions from public health threats, trade disputes, and geopolitical challenges.

In addition, by deploying state-of-the-art flow chemistry, continuous manufacturing technology, and other advanced manufacturing processes, Phlow’s goal is to help customers achieve faster regulatory approvals resulting in increased patient access to life-changing medicines and reduced drug shortages that continue to impact Americans.

“At Phlow, our U.S.-based public benefit corporation is focused firmly on impact, solving for critical pharmaceutical supply chain challenges by moving far beyond the boundaries of the status quo in pharmaceutical development and manufacturing,” said Eric Edwards, co-founder and CEO of Phlow. “Our recent investment round further ensures our bold mission and progress towards helping to solve for drug shortage challenges while providing end-to-end solutions in the U.S. that are fully integrated,comprehensive, environmentally friendly and cost competitive.”

Dave Ryan, Phlow’s chief financial officer said, “On behalf of our growing Phlow team, we are deeply appreciative that our investors have exhibited continued confidence and trust in not only our shared vision but our proven ability to execute. Together, we are revolutionizing the science behind life-changing medicines and creating unprecedented levels of access that is helping to improve the health of our nation.”